Study List:

Study 351:
  NCT Number:                   NCT04213274
  Title:                        Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Schnitzler Syndrome|Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
  Interventions:                Biological: 80 mg RPH-104|Drug: Placebo
  Outcome Measures:             Proportion of subjects with complete response (Schnitzler Disease Activity Score (SDAS = 0)) to therapy on Day 14 in the RPH-104 group as compared to the placebo group|Change from baseline to Day 14 in subject-reported symptom severity of SchS: Patient-reported Severity of Schnitzler Syndrome Scale (PR-SchS Scale)|Proportion of subjects with normalized serum amyloid A (SAA) and C-reactive protein (CRP) at Days 14 and 28|Change from baseline to Day 14 and Day 28 in CRP and SAA|Proportion of subjects with complete response (SDAS = 0) to therapy on Day 28 by treatment sequence based on SDAS using the Physician's Global Assessment (PGA) and the CRP result|Proportion of subjects with partial response by treatment sequence on Days 14 and 28
  Sponsor/Collaborators:        R-Pharm Overseas, Inc.|Worldwide Clinical Trials|R-Pharm
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   14
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CL04018066
  Start Date:                   January 31, 2020
  Primary Completion Date:      August 1, 2020
  Completion Date:              January 1, 2021
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213274

Study 352:
  NCT Number:                   NCT04213261
  Title:                        A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
  Acronym:                      DEFI-RDEB
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Recessive Dystrophic Epidermolysis Bullosa
  Interventions:                Biological: FCX-007 (no generic name is established; see below for FCX-007 description)
  Outcome Measures:             Percentage change in surface area of wound|≥50% Closure of Wounds compared to Baseline using Imaging System|Change in Patient Global Impression of Epidermolysis Bullosa Wound Severity of Target Wounds
  Sponsor/Collaborators:        Fibrocell Technologies, Inc.|Castle Creek Pharmaceuticals, LLC
  Gender:                       All
  Age:                          2 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   20
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    FI-EB-002
  Start Date:                   January 2020
  Primary Completion Date:      December 2020
  Completion Date:              March 2021
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    Stanford University, Stanford, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Dell Children's Medical Group, Austin, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213261

Study 353:
  NCT Number:                   NCT04213248
  Title:                        Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dry Eye
  Interventions:                Drug: Umbilical Mesenchymal Stem Cells derived Exosomes
  Outcome Measures:             Changes in Ocular Surface Disease Index (OSDI) Score|Changes in tear secretion amount by Schirmer's Test|Changes in Tear break time|Changes in Ocular Surface Staining|Changes in best corrected visual acuity (BCVA).|Changes in conjunctiva redness score|Changes in tear meniscus height
  Sponsor/Collaborators:        Zhongshan Ophthalmic Center, Sun Yat-sen University
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   27
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2019KYPJ048
  Start Date:                   January 2020
  Primary Completion Date:      May 2020
  Completion Date:              May 2020
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           January 1, 2020
  Locations:                    Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213248

Study 354:
  NCT Number:                   NCT04213235
  Title:                        Educational Materials Development for Physical Activity in CAncer
  Acronym:                      EDuCA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Mixed Cancer
  Interventions:                Behavioral: Physical activity
  Outcome Measures:             Physical activity level - using Godin's Leisure Time Exercise Questionnaire (GLTEQ)|quality of life - using European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire" (EORTC QLQ C-30)|Sedentary behavior - using Sedentary Behaviour Questionnaire (SBQ)
  Sponsor/Collaborators:        Universita di Verona
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   25
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  Other IDs:                    67002
  Start Date:                   January 1, 2020
  Primary Completion Date:      November 1, 2020
  Completion Date:              November 1, 2020
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    University of Verona, Verona, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213235

Study 355:
  NCT Number:                   NCT04213222
  Title:                        Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases
  Acronym:                      ROBOT
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Colon Cancer|Rectal Cancer|Liver Metastases
  Interventions:                Drug: Bevacizumab
  Outcome Measures:             estimated ORR|estimated PFS|estimated OS
  Sponsor/Collaborators:        Peking University People's Hospital
  Gender:                       All
  Age:                          18 Years to 80 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   300
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    20181113
  Start Date:                   January 2020
  Primary Completion Date:      June 2022
  Completion Date:              December 2023
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213222

Study 356:
  NCT Number:                   NCT04213209
  Title:                        Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Peripheral T Cell Lymphoma and Pediatric Hodgkin Lymphoma
  Interventions:                Drug: Brentuximab Vedotin (Genetical Recombination)
  Outcome Measures:             Percentage of Participants who Experienced Peripheral Neuropathy|Percentage of Participants who Experienced Myelosuppression Resulted in Neutropenia|Percentage of Participants who Experienced Lung Disorder|Percentage of Participants Who Achieve or Maintain Any Best Response for PTCL excluding adult T-cell leukemia/lymphoma (ATLL), or Pediatric HL|Percentage of Participants Who Achieve or Maintain Any Best Response for ATLL|Percentage of Participants with Grade 3 or Higher Adverse Event (AE)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   86
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    C25021
  Start Date:                   December 31, 2019
  Primary Completion Date:      December 31, 2022
  Completion Date:              December 31, 2022
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    Takeda Selected Site, Tokyo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213209

Study 357:
  NCT Number:                   NCT04213196
  Title:                        Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Healthy Volunteers
  Interventions:                Drug: HSK21542
  Outcome Measures:             Ramsay|VAS|Peak concentration (Cmax)|Area under the concentration-time curve（AUC）|Tmax|Total clearance
  Sponsor/Collaborators:        Sichuan Haisco Pharmaceutical Group Co., Ltd.|Second Affiliated Hospital, School of Medicine, Zhejiang University
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   58
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other
  Other IDs:                    HSK21542-102
  Start Date:                   December 30, 2019
  Primary Completion Date:      April 15, 2020
  Completion Date:              June 30, 2020
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213196

Study 358:
  NCT Number:                   NCT04213183
  Title:                        Association of Eye With Hepatobiliary Disorders :Qualitative Analysis Via Deep Learning
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Ophthalmology|Artificial Intelligence|Hepatobiliary Disease
  Interventions:                Diagnostic Test: Hepatobiliary Disorders
  Outcome Measures:             area under the receiver operating characteristic curve of the deep learning system|sensitivity and specificity of the deep learning system
  Sponsor/Collaborators:        Sun Yat-sen University|Third Affiliated Hospital, Sun Yat-Sen University|Huadu District People's Hospital of Guangzhou|iKang Medical International
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   1527
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    AEHD-2019
  Start Date:                   December 1, 2018
  Primary Completion Date:      December 25, 2019
  Completion Date:              December 31, 2020
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity, Guangzhou, Guangdong, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213183

Study 359:
  NCT Number:                   NCT04213170
  Title:                        Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Brain Metastases|Non Small Cell Lung Cancer|Sintilimab|Bevacizumab
  Interventions:                Drug: sintilimab
  Outcome Measures:             iORR|iPFS|ORR|PFS
  Sponsor/Collaborators:        Sun Yat-sen University
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   60
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    B2019-050-01
  Start Date:                   April 29, 2019
  Primary Completion Date:      December 2022
  Completion Date:              December 2022
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 30, 2019
  Locations:                    Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213170

Study 360:
  NCT Number:                   NCT04213157
  Title:                        Laparoscopic Partial Nephrectomy for cT1 Tumors
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Renal Cancer|Renal Neoplasm|Renal Cell Carcinoma|Surgery|Surgery--Complications|Renal Functional Abnormality|Oncology|Oncology Problem|Kidney Ischemia|Kidney Injury|Urologic Neoplasms|Urologic Cancer|Kidney Neoplasms
  Interventions:                
  Outcome Measures:             Operation time|Blood loss|warm ischemia time|intraoperative complication|Postoperative complication|functional outcomes|surigcal margin status|Relative decrease in renal function|CKD stage upgrading|Oncological outomes
  Sponsor/Collaborators:        Samsun Liv Hospital|Ondokuz Mayıs University
  Gender:                       All
  Age:                          18 Years to 82 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   292
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    OMU KAEK 2019/241
  Start Date:                   March 15, 2019
  Primary Completion Date:      August 30, 2019
  Completion Date:              November 10, 2019
  First Posted:                 December 30, 2019
  Results First Posted:         
  Last Update Posted:           December 31, 2019
  Locations:                    Liv hospital samsun, Samsun, Turkey|Ondokuz Mayıs University, Samsun, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04213157

